Skip to main navigation
Skip to search
Skip to main content
Augusta University Research Profiles Home
Help & FAQ
Home
Profiles
Research units
Equipment
Grants
Scholarly Output
Datasets
Activities
Prizes
Search by expertise, name or affiliation
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial
EPIC investigators
Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
208
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Atrial Fibrillation
2%
Blood Vessels
1%
Clinical Trials Data Monitoring Committees
4%
Cytogenetics
2%
Exanthema
2%
Imatinib Mesylate
68%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
63%
Leukemia, Myeloid, Chronic Phase
7%
Lipase
3%
Neutropenia
2%
Pancreatitis
2%
Pharmaceutical Preparations
1%
Philadelphia Chromosome
3%
ponatinib
100%
Preliminary Data
3%
Protein-Tyrosine Kinases
2%
Risk Assessment
2%
Safety
5%
Therapeutics
0%
Thrombocytopenia
8%